m+Medelevator.RU
← Поиск публикаций
Frontiers in medicine · 2026

Acyl-CoA synthetase long-chain family member 4-A novel prognostic marker in cutaneous melanoma.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Paria Soumya, Lapides Rebecca, Saravi Babak, Rajagopal Anjali, Torrez Alina M, Kölblinger Peter, Wang-Evers Michael, Manstein Dieter, Navarini Alexander A, Lazar Peter, Kemény Lajos V, Sarek Grzegorz, Adhikari Kaustubh, Németh István B, Roider Elisabeth

Аннотация

Ferroptosis is an iron-dependent form of regulated cell death driven by lipid peroxidation. Acyl coenzyme A (Acyl-CoA) synthetase long-chain family member 4 (ACSL4) promotes ferroptosis by enriching cellular membranes with polyunsaturated fatty acids, yet its prognostic relevance in melanoma remains unclear. We conducted a retrospective analysis of 63 patients with melanoma to evaluate associations between ACSL4 expression and overall survival (OS), metastasis-free survival (MFS), and disease-free survival (DFS). Correlation analyses and Cox proportional hazards (CoxPH) models were used to identify prognostic factors, and immune cell infiltration was assessed in tumor samples. Higher ACSL4 expression was consistently associated with improved OS, MFS, and DFS in cutaneous melanoma. ACSL4 levels also correlated with greater immune cell infiltration within the tumor microenvironment. Notably, metastatic melanoma cases exhibited higher ACSL4 expression than non-metastatic cases; however, within cutaneous melanoma, elevated ACSL4 remained linked to more favorable survival outcomes. Together, these findings position ACSL4 as a promising prognostic biomarker in melanoma and suggest a potential connection between ferroptosis biology and antitumor immunity. While the study is retrospective and correlative, it provides a strong rationale for prospective validation and mechanistic studies to test whether modulating ACSL4-driven ferroptosis can improve clinical outcomes.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты